Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

177542Total assets 

$  110,134$  149,700Liabilities and stockholders' equity Current liabilities:Accounts payable and accrued expenses 

$   17,775$
4,277Deferred revenue, current portion 

3,4293,429Total current liabilities 

21,2047,706Deferred revenue, less current portion 

39,42942,000Other long-term liabilities 

140288Commitments and contingenciesStockholders' equity:Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2012 and December 31, 2011; noshares issued and outstanding atat September 30, 2012 and December 31, 2011--Common stock, $.001 par value, 300,000,000 sharesauthorized at September 30, 2012 and December 31, 2011;70,727,827 and 61,285,514 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively

7161Additional paid-in capital 

453,624446,357Accumulated other comprehensive income (loss)

15(2)Accumulated deficit

(404,349)(346,710)Total stockholders' equity 

49,36199,706Total liabilities and stockholders' equity 

$  110,134$  149,700 Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2012201120122011Revenues:Collaborative agreement 

$
857$
857$
2,571$
2,571License revenue ---971Total revenues 

8578572,5713,542Operating expenses:Research and development 

25,8061,53945,42811,237General and administrative 

5,6513,90714,90515,870Total operating expenses 

31,4575,44660,33327,107Loss from operations 

(30,600)(4,589)(57,762)(23,565)Other income (expense):Interest income 

36912535Interest expense 

--(2)(221)Total other income (expense) <
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... (NYSE: HRC ) invites you to listen to ... Conference in New York City on February 15, 2012, at ... to the live discussion via the internet link at  http://ir.hill-rom.com/events.cfm ... recorded replay of the discussion will be available one hour ...
... growing stronger and stronger for one of the most ... on February 21-22, 2012 at the Renaissance Zurich Hotel ... 150 top pharmaceutical executives already attending, people are already ... among the industry,s influential decision makers," says conference organizer ...
Cached Medicine Technology:World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event 2
(Date:9/21/2014)... public health authorities focus on the physical activity benefits ... of Montreal reveals that for children, playing has no ... activity that is fun, done alone or with friends, ... pleasure, but also to combat boredom, sadness, fear, or ... play, authorities put aside several aspects of play that ...
(Date:9/21/2014)... PhUSE is proud to announce Dr. Pritpal Tamber, ... speakers for their 10th annual conference which is themed ... in 2013 , Charles Sabine in 2012 ... again presents high-calibre speakers to talk about relevant topics ... information. , Dr. Pritpal Tamber is a "health explorer" ...
(Date:9/21/2014)... 2014 Burnaby Physiotherapists at Absolute PhysioCare ... in order to help them with preventative care. This ... clinic that will help clients understand their problem in ... active participation in the healing process. With higher knowledge ... be able to facilitate the therapy that is initiated ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... that help businesses and manufacturers perform tests on items ... In an increasingly regulated society, pressure on operators to ... higher than ever. A greater number of government safety ... of manufacturers' goods prior to sale. Although revenue briefly ...
(Date:9/21/2014)... September 21, 2014 Over the past ... drugs to inundate the market, thereby cutting into revenue ... industry. According to data from Industry Canada, the loss ... industry $1.8 and $2.5 billion in 2010 and 2012, ... patent exclusivity, which has hampered revenue growth, many pharmaceutical ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... A new season of Dancing With The Stars begins with new cast members and a new diet firmly in ... Nicole Scherzinger , Kate Gosselin , Shannen Doherty , new Olympic champion, Evan Lysacek , ... Jake Pavelka . , ... ...
... March 22 CCH has issued a Special Tax ... reform legislation. With the passage of the Patient Protection and ... Education Tax Credits Reconciliation Act in the House, the stage ... signing by the president to wind up the long legislative path ...
... founder of healthcare IT company, Ingenious Med, is among the more than 150 hospitalists nationwide who have earned the inaugural designation of Senior Fellow in Hospital Medicine (SFHM). , ... , ... ... ...
... psychiatric drugs. , ... , , ... ... The research was conducted by Thomson Reuters, ...
... supernatural forces are common in Ghana and other African ... witchcraft. Over thirty per cent of its inhabitants believe ... of HIV/AIDS. When meeting Ghanian colleagues, professor and ... confronted with intellectually challenging issues. "The spread ...
... Everett and Walid Saleh, a scholar of religion ... selected to receive a highly competitive New Directions Fellowship ... It is the first time the fellowships, created in ... The New Directions Fellowships are unique in ...
Cached Medicine News:Health News:The Fresh Diet Dances With The Stars Keeping the Cast in Shape and on Its Toes 2Health News:The Fresh Diet Dances With The Stars Keeping the Cast in Shape and on Its Toes 3Health News:CCH Issues Briefing on Tax Provisions of Health Care Reform Legislation 2Health News:CCH Issues Briefing on Tax Provisions of Health Care Reform Legislation 3Health News:CCH Issues Briefing on Tax Provisions of Health Care Reform Legislation 4Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 2Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 3Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 4Health News:Thomson Reuters Study Offers New Insight on How Physicians Prescribe Psychiatric Drugs 2Health News:Thomson Reuters Study Offers New Insight on How Physicians Prescribe Psychiatric Drugs 3Health News:Thomson Reuters Study Offers New Insight on How Physicians Prescribe Psychiatric Drugs 4Health News:Thomson Reuters Study Offers New Insight on How Physicians Prescribe Psychiatric Drugs 5Health News:Modern medicine conquers witchcraft 2Health News:Modern medicine conquers witchcraft 3Health News:Modern medicine conquers witchcraft 4Health News:University of Toronto scholars receive prestigious New Directions Fellowships 2
Albumin FS for determination of albumin in serum or plasma. For Hitachi 704 / 911. Available with Calibrator: Trucal U and Controls: Trulab N and Trulab P....
Intended for the quantitative determination of albumin in serum or plasma. Reaction: Endpoint. Wavelength: 628 nm. Linearity: 8 g/dl (80 g/l). Ready to use liquid reagent....
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
Medicine Products: